These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 9621480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Swain SM.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R.
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [Abstract] [Full Text] [Related]

  • 7. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
    Blum RH.
    Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
    [No Abstract] [Full Text] [Related]

  • 8. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
    Lipshultz SE.
    J Clin Oncol; 1996 Feb; 14(2):328-31. PubMed ID: 8636739
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M, Vici P.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cardiotoxicity and cardioprotection during chemotherapy.
    Hochster H, Wasserheit C, Speyer J.
    Curr Opin Oncol; 1995 Jul; 7(4):304-9. PubMed ID: 7578376
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
    Am J Health Syst Pharm; 1995 Oct 01; 52(19):2076. PubMed ID: 8535936
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Langer SW, Jensen PB, Sehested M.
    Cardiovasc Toxicol; 2007 Oct 01; 7(2):151-3. PubMed ID: 17652821
    [Abstract] [Full Text] [Related]

  • 19. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS, Scott LJ.
    Drugs; 2005 Oct 01; 65(7):1005-24. PubMed ID: 15892593
    [Abstract] [Full Text] [Related]

  • 20. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
    Gershanovich ML.
    Vopr Onkol; 2001 Oct 01; 47(1):119-22. PubMed ID: 11317530
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.